文献速递临床试验与 GCP流行病学与生物统计

血管加压素联合儿茶酚胺与单用儿茶酚胺对分布性休克患者房颤风险关联的系统综述与荟萃分析

Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2018-01-01

结果显示联合治疗与房颤风险降低相关(RR 0.77,95%CI 0.67-0.88),死亡率总体RR 0.89(95%CI 0.82-0.97),但低偏倚风险试验中不显著。

要点

  • 血管加压素联合儿茶酚胺较单用可降低分布性休克患者房颤风险。
  • 总体死亡率RR 0.89,但低偏倚风险试验中未达统计学显著。
  • 肾脏替代治疗需求总体无显著差异,低偏倚风险试验中RR 0.70。

核心结论

  • 在分布性休克患者中,血管加压素联合儿茶酚胺较单用儿茶酚胺与房颤风险降低相关。
  • 次要结局结果不一,死亡率总体获益在低偏倚风险试验中未持续。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和CENTRAL至2018年2月。
  • 采用随机效应模型合并数据,主要结局为房颤。

主要发现

  • 房颤风险:血管加压素组较对照组RR 0.77(95%CI 0.67-0.88),风险差-0.06(95%CI -0.13-0.01),证据质量高。
  • 死亡率:总体RR 0.89(95%CI 0.82-0.97),风险差-0.04(95%CI -0.07-0.00);低偏倚风险试验RR 0.96(95%CI 0.84-1.11)。
  • 肾脏替代治疗:总体RR 0.74(95%CI 0.51-1.08),风险差-0.07(95%CI -0.12--0.01);低偏倚风险试验RR 0.70(95%CI 0.53-0.92,交互P=0.77)。
  • 其他结局(心肌损伤、室性心律失常、卒中、ICU及住院时长) pooled风险无显著差异。

关键数值与推荐

  • 房颤风险降低具有高质量证据支持(RR 0.77,95%CI 0.67-0.88)。
  • 死亡率总体获益但低偏倚风险试验中不显著(RR 0.96,95%CI 0.84-1.11)。
  • 肾脏替代治疗需求在低偏倚风险试验中显著降低(RR 0.70,95%CI 0.53-0.92)。

临床怎么用

  • 对于分布性休克患者,可考虑在儿茶酚胺基础上加用血管加压素以降低房颤风险。
  • 临床决策需权衡房颤风险降低与次要结局的不确定性。

局限性

  • 次要结局结果在不同偏倚风险试验中不一致,需谨慎解读。
  • 检索截止2018年2月,未纳入此后发表的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Vasopressin is an alternative to catecholamine vasopressors for patients with distributive shock-a condition due to excessive vasodilation, most frequently from severe infection. Blood pressure support with a noncatecholamine vasopressor may reduce stimulation of adrenergic receptors and decrease myocardial oxygen demand. Atrial fibrillation is common with catecholamines and is associated with adverse events, including mortality and increased length of stay (LOS). OBJECTIVES: To determine whether treatment with vasopressin + catecholamine vasopressors compared with catecholamine vasopressors alone was associated with reductions in the risk of adverse events. DATA SOURCES: MEDLINE, EMBASE, and CENTRAL were searched from inception to February 2018. Experts were asked and meta-registries searched to identify ongoing trials. STUDY SELECTION: Pairs of reviewers identified randomized clinical trials comparing vasopressin in combination with catecholamine vasopressors to catecholamines alone for patients with distributive shock. DATA EXTRACTION AND SYNTHESIS: Two reviewers abstracted data independently. A random-effects model was used to combine data. MAIN OUTCOMES AND MEASURES: The primary outcome was atrial fibrillation. Other outcomes included mortality, requirement for renal replacement therapy (RRT), myocardial injury, ventricular arrhythmia, stroke, and LOS in the intensive care unit and hospital. Measures of association are reported as risk ratios (RRs) for clinical outcomes and mean differences for LOS. RESULTS: Twenty-three randomized clinical trials were identified (3088 patients; mean age, 61.1 years [14.2]; women, 45.3%). High-quality evidence supported a lower risk of atrial fibrillation associated with vasopressin treatment (RR, 0.77 [95% CI, 0.67 to 0.88]; risk difference [RD], -0.06 [95% CI, -0.13 to 0.01]). For mortality, the overall RR estimate was 0.89 (95% CI, 0.82 to 0.97; RD, -0.04 [95% CI, -0.07 to 0.00]); however, when limited to trials at low risk of bias, the RR estimate was 0.96 (95% CI, 0.84 to 1.11). The overall RR estimate for RRT was 0.74 (95% CI, 0.51 to 1.08; RD, -0.07 [95% CI, -0.12 to -0.01]). However, in an analysis limited to trials at low risk of bias, RR was 0.70 (95% CI, 0.53 to 0.92, P for interaction = .77). There were no significant differences in the pooled risks for other outcomes. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, the addition of vasopressin to catecholamine vasopressors compared with catecholamines alone was associated with a lower risk of atrial fibrillation. Findings for secondary outcomes varied.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29801010. doi:10.1001/jama.2018.4528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。